VIRUS SAFETY TESTING SERVICES MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Global Virus Safety Testing Services Market Size and Forecast – 2025 to 2032

The Global virus safety testing services market is estimated to be valued at USD 682.4 million in 2025 and is expected to reach USD 1,987.5 million by 2032, exhibiting a compound annual growth rate (CAGR) of 16.50% from 2025 to 2032. The market growth is driven by the increasing demand for ensuring the safety and quality of biopharmaceutical products, stringent regulatory requirements, and the growing prevalence of chronic diseases.

Key Takeaways of the Virus Safety Testing Services Market:

• In 2025, the viral detection testing segment is expected to hold the largest share of the market by testing type at 29.2%, driven by the increasing demand for early identification of viral infections across various applications.
• By application, the vaccines segment leads the virus safety testing services market with an estimated 28.2% share in 2025, reflecting the critical role of virus safety in vaccine development and production
• Among end users, the pharmaceutical companies segment is expected to account for the highest market share at 34.2% in 2025, due to their extensive use of virus testing services throughout the drug development lifecycle.
• North America is expected to lead the market, holding a share of 38.3% in 2025. Asia Pacific is anticipated to be the fastest-growing region, with a market share of 25.2% in 2025.

Market Overview:

The trend in the virus safety testing services market is towards the adoption of advanced technologies, such as next-generation sequencing (NGS) and polymerase chain reaction (PCR), to enhance the accuracy and speed of virus detection. Additionally, there is a growing focus on outsourcing virus safety testing services to specialized contract research organizations (CROs) to reduce costs and improve efficiency. The market is also witnessing a shift towards the development of cell-based assays and the use of animal-free testing methods to address ethical concerns and comply with regulatory guidelines.

Currents Events and their Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Analysis

To learn more about this report, Request sample copy

Virus Safety Testing Services Market Insights, By Testing Type - Viral Detection Testing Dominates the Market due to Increasing Demand for Early Virus Identification

In terms of testing type, the viral detection testing segment is expected to contribute the highest share of the market with 29.2% in 2025 owing to the growing need for early identification of viral infections in various applications. The increasing prevalence of viral diseases worldwide has driven the demand for accurate and reliable viral detection methods. Viral detection testing plays a crucial role in identifying the presence of viruses in biological samples, ensuring the safety and quality of products such as vaccines, antibodies, and cell therapies.

The dominance of viral detection testing can be attributed to several factors. Firstly, rapid advancements in molecular diagnostic techniques, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS), have significantly improved the sensitivity and specificity of viral detection.

For instance, in October 2024, the World Health Organization (WHO), the United Nations agency responsible for international public health, approved the first mpox diagnostic test under its Emergency Use Listing (EUL). The test—Alinity m MPXV assay, developed by Abbott Molecular Inc.—aims to improve access to rapid and accurate mpox testing, especially in outbreak-affected regions.

Virus Safety Testing Services Market Insights, By Application - Vaccines Segment Leads the Market due to Rising Global Immunization Efforts

In terms of application, the vaccines segment is expected to contribute the highest share of the virus safety testing services market with a share of 28.2% in 2025. The growth of this segment can be attributed to the increasing global efforts to develop and distribute vaccines for various infectious diseases. Vaccines are the most effective means of preventing viral infections and have been instrumental in eradicating several life-threatening diseases, such as smallpox and polio.

The high share of the vaccines segment is driven by several factors. Firstly, the ongoing COVID-19 pandemic has highlighted the critical importance of vaccines in controlling the spread of viral infections. The unprecedented global collaboration in vaccine development and distribution has led to a surge in demand for virus safety testing services to ensure the safety and efficacy of COVID-19 vaccines.

Virus Safety Testing Services Market Insights, By End User - Pharmaceutical Companies Dominate the End User Segment due to Stringent Safety Regulations

In terms of end user, the pharmaceutical companies segment is projected to contribute the highest share of the virus safety testing services market with a share of 34.2% in 2025. The dominance of pharmaceutical companies in this segment can be attributed to the stringent safety regulations and quality standards imposed on pharmaceutical products.

The high share of pharmaceutical companies in the end user segment is driven by several factors. Firstly, the increasing complexity of pharmaceutical manufacturing processes has heightened the risk of viral contamination. Pharmaceutical companies rely on virus safety testing services to identify potential viral contaminants at various stages of the manufacturing process, from raw materials to finished products. This helps them maintain the highest standards of quality and safety in their products.

For instance, in May 2023, Charles River Laboratories, a pharmaceutical company, partnered with Wheeler Bio to establish and operate a RightSource Laboratory. This embedded, good manufacturing practice-compliant. quality control facility is designed to streamline biologics development for early-stage biopharma companies by enabling in-house biological safety testing and reducing time-to-market.

Regional Insights:

To learn more about this report, Request sample copy

North America Virus Safety Testing Services Market Analysis and Trends

In North America, the dominance in the virus safety testing services market with an estimated share of 38.3% in 2025 can be attributed to several factors. The region boasts a well-established healthcare infrastructure, stringent regulatory standards, and a strong presence of major pharmaceutical and biotechnology companies. The U.S., in particular, plays a significant role in driving the market growth, with its advanced research facilities, robust funding for drug development, and high demand for ensuring the safety of biological products. Companies like Charles River Laboratories, WuXi AppTec, and Eurofins Scientific have a strong foothold in the region, offering comprehensive virus safety testing services to clients across the pharmaceutical and biotechnology sectors.

Asia Pacific Virus Safety Testing Services Market Analysis and Trends

Meanwhile, the Asia Pacific region is expected to exhibit the fastest growth in the virus safety testing services market with a share of 25.2% in 2025. This growth can be ascribed to the rapidly expanding pharmaceutical and biotechnology industries in countries like China, India, and South Korea. These countries have witnessed significant investments in research and development, along with the establishment of world-class manufacturing facilities. The increasing adoption of novel therapeutics, such as cell and gene therapies, in the region has further fueled the demand for virus safety testing services. Moreover, favorable government policies, such as tax incentives and streamlined regulatory processes, have attracted global players to set up their operations in the Asia Pacific region. Companies like WuXi Biologics and Samsung Biologics have emerged as key players, catering to the growing demand for virus safety testing services in the region.

Global Virus Safety Testing Services Market Outlook for Key Countries:

U.S. Virus Safety Testing Services Market Trends

The U.S. market for virus safety testing services is characterized by a strong emphasis on product safety and regulatory compliance. The country is home to numerous leading pharmaceutical and biotechnology companies that rely on specialized testing services to ensure the safety of their products. The U.S. Food and Drug Administration (FDA) plays a crucial role in setting stringent guidelines and standards for virus safety testing, driving the demand for reliable and accurate testing services. Major players like Charles River Laboratories and Eurofins Scientific have a significant presence in the U.S. virus safety testing services market, offering a wide range of testing services, including cell-based assays, polymerase chain reaction (PCR) testing, and viral clearance studies.

For instance, in December 2024, the U.S. Department of Agriculture (USDA), the federal agency overseeing farming, food safety, and rural development in the U.S., launched a national initiative to test unpasteurized milk from dairy farms to monitor the spread of H5N1 avian influenza.

Japan Virus Safety Testing Services Market Trends

The Japan virus safety testing services market is witnessing notable growth, driven by rising biopharmaceutical R&D, stringent regulatory frameworks, and increasing demand for safe biologics and vaccines. With a strong presence of domestic pharmaceutical companies and ongoing innovation in gene therapies and regenerative medicine, the need for comprehensive virus detection and clearance testing has intensified. The market is also seeing a shift toward advanced technologies such as next-generation sequencing (NGS) and PCR-based assays, offering higher accuracy and faster turnaround times.

For instance, in February 2025, Nippon Paint Co., Ltd., a Japan-based subsidiary of Nippon Paint Holdings, launched two new anti-viral, anti-bacterial water-based paints in China under its PROTECTON brand—Floor VK Clear for floors and Interior Wall VK Coat for walls. The products use copper technology to eliminate over 99% of viruses and bacteria, offering high durability and strong adhesion even on porcelain tiles.

India Virus Safety Testing Services Market Trends

India continues to be a prominent player in the virus safety testing services market, driven by its large pool of skilled professionals, cost-effective services, and growing pharmaceutical and biotechnology sectors. The country has emerged as a hub for contract research and manufacturing services, attracting global clients seeking reliable and efficient testing solutions. The Indian government's focus on promoting the biotechnology industry and streamlining regulatory processes has further supported the growth of the virus safety testing services market in the country.

For instance, in July 2023, Recipharm, a global Contract Development and Manufacturing Organization (CDMO), opened a new 5,000 sq. ft. analytical lab in Bengaluru, India to strengthen its global testing capabilities. Fully cGMP/cGLP compliant, the lab offers advanced services for nitrosamines, extractables and leachables, and elemental impurity testing. It supports pharmaceutical and biotech clients in areas such as oral solids, injectables, inhalation therapies, and vaccines.

U.K. Virus Safety Testing Services Market Trends

The U.K. virus safety testing services market is advancing through strong public–private partnerships, led by innovations such as Oxford Nanopore Technologies’ real-time pathogen surveillance across National Health Service (NHS) sites. There is growing adoption of Next-Generation Sequencing (NGS) technologies, which enable faster and more accurate virus detection in biologics and vaccines. The focus is shifting from reactive to preventive virus safety testing, supported by government funding and the integration of efforts across healthcare providers, research institutions, and regulatory bodies.

For instance, in May 2024, Eurofins BioPharma Product Testing, a leading provider of GMP-compliant testing services for biopharmaceuticals, announced a major expansion of its viral safety capabilities. The company is doubling its laboratory space and launching a new dedicated facility for viral vector and Advanced Therapeutic Medicinal Product (ATMP) testing.

End User Feedback and Unmet Needs

• End users in the virus safety testing services market—including pharma firms, biologics developers, and public health agencies—emphasize the need for reliability, regulatory compliance, and fast turnaround. Pfizer partnered with Charles River Laboratories for efficient virus clearance testing during biologics development, while Moderna worked with Sartorius Stedim BioOutsource to support mRNA vaccine production through customized protocols. These collaborations highlight how leading players benefit from flexible and specialized testing services.
• Unmet needs persist—especially among SMEs and academic labs—related to high costs, limited-service modularity, and lack of digital integration. Challenges also arise in adapting protocols for novel therapies like gene and mRNA-based products. Addressing these through scalable pricing, tech-enabled platforms, and tailored support can expand access, improve satisfaction, and foster innovation, while creating new opportunities for providers and encouraging regulatory alignment.

Market Players, Key Developments, and Competitive Intelligence:

To learn more about this report, Request sample copy

Key Developments:

• In October 2024, SGS SA, a Switzerland-based global leader in testing, inspection, and certification, expanded its biopharmaceutical testing services to meet the growing global demand for large-molecule drug development. The expansion strengthens its support for biologics across multiple development stages, including cell bank safety assessments, product characterization, method development, and final product release.
• In October 2024, Asahi Kasei Bioprocess, a Japan-based subsidiary of the Asahi Kasei Group specializing in bioprocess solutions, launched the Planova FG1, a next-generation virus removal filter with higher flux for biotherapeutic manufacturing. As part of its broader portfolio that includes biosafety testing services and CDMO operations, the new filter enhances productivity and supports the growing global demand for monoclonal antibodies and other biopharmaceuticals.
• In October 2024, Merck, a global science and technology leader based in Germany, inaugurated a new biosafety testing facility in Maryland, U.S. This marks the company’s largest-ever investment in contract testing. The facility will serve as an integrated hub for automation and technology development, addressing the fast-growing global demand for biosafety testing services.
• In August 2024, SGS SA launched specialized services in North America to further support the increasing demand for biologics and advanced therapies. These services focus on large molecule bioanalysis, pharmacokinetics, immunogenicity, and biomarker analysis, addressing the expanding pipeline of monoclonal antibodies, gene therapies, and cell-based therapeutics

Top Strategies Followed by Global Virus Safety Testing Services Market Players

• Established players in the global virus safety testing services market are focusing on extensive research and development to innovate high-performance products. These companies are investing heavily in R&D to develop advanced testing methods and technologies that can detect a wide range of viruses with high accuracy and sensitivity. They are also exploring new areas of virus safety testing, such as cell and gene therapies, to expand their market reach.
  • For instance, in May 2021, Charles River Laboratories, a company in preclinical and clinical laboratory services, announced its plan to acquire Vigene Biosciences, a provider of viral vector-based gene delivery solutions. The acquisition is intended to enhance Charles River’s gene therapy service offerings.

• Mid-level players in the market are focusing on delivering cost-effective solutions to target price-sensitive consumers. They are developing testing services that offer a good balance between quality and affordability, making them accessible to a wider range of customers. These companies are also forming collaborations with other players in the market to boost their technology and production capabilities, as well as their market presence.
  • For instance, in May 2024, Eurofins BioPharma Product Testing, a leading provider of GMP-compliant testing services for biopharmaceuticals, announced a major expansion of its viral safety capabilities. The company is doubling its laboratory space and launching a new dedicated facility for viral vector and Advanced Therapeutic Medicinal Product (ATMP) testing.

• Small-scale players in the virus safety testing services market are targeting niche markets with unique features or innovative products. They are specializing in specific areas of virus safety testing, such as adventitious agent testing or viral clearance studies, to differentiate themselves from larger competitors.
  • For instance, in June 2023, Texcell SA, a global contract research organization specializing in viral safety testing and immunoprofiling, launched a new testing facility in North America. The expansion aims to strengthen its capabilities in viral safety and clearance testing for biotherapeutics and medical devices.

Market Report Scope

Market Dynamics

To learn more about this report, Request sample copy

Virus Safety Testing Services Market Driver - Rising demand for biologics and gene therapies

The global virus safety testing services market is witnessing a significant driver in the form of rising demand for biologics and gene therapies. As the healthcare industry continues to advance, there has been a substantial increase in the development and commercialization of innovative biologics and gene therapy products. These cutting-edge treatments offer immense potential in addressing various diseases and genetic disorders, leading to a surge in their adoption. However, ensuring the safety and efficacy of these products is of utmost importance, as they are derived from living organisms and can pose potential risks associated with viral contamination. Consequently, the growing demand for biologics and gene therapies has fueled the need for comprehensive virus safety testing services.

For instance, in April 2025, AGC Biologics, a global contract development and manufacturing organization (CDMO), introduced a new Cell and Gene Technologies Division to strengthen virus safety support for cell and gene therapy developers. With facilities in the U.S., Italy, and Japan, and proprietary platforms such as ProntoLVV and BravoAAV, the division helps accelerate GMP manufacturing while ensuring viral safety and regulatory compliance in the virus safety testing services market.

Virus Safety Testing Services Market Opportunity - Advancements in testing technologies

The global virus safety testing services market is poised to benefit from the rapid advancements in testing technologies. Innovations in molecular biology, such as next-generation sequencing (NGS) and polymerase chain reaction (PCR) techniques, have revolutionized virus detection and identification. These cutting-edge technologies enable faster, more sensitive, and more accurate virus safety testing, thereby enhancing the efficiency and reliability of the testing process. Furthermore, the integration of automation and high-throughput screening systems has the potential to streamline testing workflows, reduce human error, and increase the overall productivity of testing facilities. The adoption of advanced data analytics and bioinformatics tools can also help in the rapid analysis and interpretation of vast amounts of testing data, enabling quicker decision-making and facilitating the identification of potential viral contaminants.

For instance, in October 2022, PathoQuest, a France- and U.S.-based leader in Next Generation Sequencing (NGS) biosafety testing for biopharmaceuticals, officially opened its new 7,000 sq. ft. facility in Pennsylvania U.S. The new site enhances the company’s capacity to serve clients across North America and globally, supporting the safe development of life-changing biologics in a key biopharma market.

Analyst Opinion (Expert Opinion) 

• The Global virus safety testing services market is witnessing robust growth, driven by stringent regulatory frameworks, rapid biopharmaceutical innovation, and the heightened global emphasis on biosafety following the COVID-19 pandemic. Technological advancements such as high-throughput sequencing and next-generation PCR methods have significantly improved detection capabilities, while regulatory bodies like the U.S. FDA and European Medicines Agency continue to enforce rigorous testing standards for biologics and gene therapies. The market also presents emerging opportunities through the expansion of viral vector-based therapies and cell & gene therapy pipelines, though it faces challenges such as high service costs, limited standardization across regions, and a shortage of specialized testing facilities in low-to-middle-income countries.
• In recent years, global conferences like the BioProcess International Conference & Exhibition (U.S), ISBioTech Annual Spring Meeting (U.S), and World Vaccine Congress (Europe/U.S) have been pivotal in fostering innovation and policy discourse in viral safety. Additionally, impactful initiatives such as Recipharm’s new analytical lab in India and Texcell SA’s North American testing facility have enhanced regional testing capacities. Furthermore, regulatory-backed pilot programs in Europe aimed at strengthening Advanced Therapy Medicinal Products (ATMP) safety frameworks are poised to shape the next phase of market evolution.

Market Segmentation

•  Testing Type Insights (Revenue, USD Mn, 2020 - 2032)
• • Viral Detection Testing
  • Viral Clearance Testing
  • Adventitious Virus Testing
  • Viral Inactivation Services
  • Antibody Production Tests
  • Retrovirus Tests
  • Other Virus Safety Tests
•  Application Insights (Revenue, USD Mn, 2020 - 2032)
• • Vaccines
  • Antibodies
  • Gene and Cell Therapy
  • Blood Product Safety
  • Tissue & Tissue-based Products
  • Regenerative Medicine
  • Other Applications
•  End User Insights (Revenue, USD Mn, 2020 - 2032)
• • Pharmaceutical Companies
  • Biopharmaceutical Companies
  • Contract Research Organizations (CROs)
  • Academic and Research Institutes
  • Others
• Regional Insights (Revenue, USD Mn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Charles River Laboratories
  • Lonza Group
  • Merck KGaA
  • WuXi AppTec
  • SGS SA
  • IDEXX Laboratories
  • Thermo Fisher Scientific
  • Eurofins Scientific
  • Abbot Laboratories
  • Becton, Dickinson and Company
  • GenScript Biotech Corporation
  • Viropro Inc.
  • PPD Inc.
  • Catalent Inc.

Sources

Primary Research Interviews:

• Interviews with regulatory officials (e.g., U.S. FDA, EMA)
• Discussions with QC/QA heads in biopharma firms
• Consultations with virologists and molecular biologists
• Input from CDMO professionals and CRO scientists
• Expert panels at biotech conferences

Databases:

• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• World Health Organization (WHO)
• Centers for Disease Control and Prevention (CDC)
• National Institutes of Health (NIH)
• Japan Pharmaceuticals and Medical Devices Agency (PMDA)

Magazines:

• BioProcess International
• Genetic Engineering & Biotechnology News (GEN)
• Pharmaceutical Technology
• Fierce Biotech
• PharmaVOICE

Journals:

• Journal of Clinical Microbiology
• Nature Biotechnology
• Journal of Biosafety and Health Education
• Journal of Pharmaceutical Sciences

Newspapers:

• The New York Times – Health
• The Guardian – Global Development & Health
• The Washington Post – Science
• The Hindu – Science/Health

Associations:

• International Alliance for Biological Standardization (IABS)
• Parenteral Drug Association (PDA)
• International Society for Pharmaceutical Engineering (ISPE)
• BioIndustry Association (BIA)
• Biotechnology Innovation Organization (BIO)

Public Domain Sources:

• WHO International Clinical Trials Registry Platform (ICTRP)
• OECD Health Statistics
• EU Clinical Trials Register
• ScienceDirect (open-access articles)

Proprietary Elements:

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI Existing Repository of Information for Last 8 Years